|
Name |
Trehangelin C
|
Molecular Formula | C22H34O13 | |
IUPAC Name* |
[(2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(Z)-2-methylbut-2-enoyl]oxyoxan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl] (Z)-2-methylbut-2-enoate
|
|
SMILES |
C/C=C(\C(=O)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]1CO)O[C@H]2O[C@@H]([C@H]([C@@H]([C@H]2O)O)OC(=O)/C(=C\C)/C)CO)O)O)/C
|
|
InChI |
InChI=1S/C22H34O13/c1-5-9(3)19(29)33-17-11(7-23)31-21(15(27)13(17)25)35-22-16(28)14(26)18(12(8-24)32-22)34-20(30)10(4)6-2/h5-6,11-18,21-28H,7-8H2,1-4H3/b9-5-,10-6-/t11-,12-,13-,14-,15-,16-,17-,18-,21-,22-/m1/s1
|
|
InChIKey |
FJOHNHZOAYDWJK-WOQQSUIUSA-N
|
|
Synonyms |
Trehangelin C
|
|
CAS | NA | |
PubChem CID | 71734191 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 506.5 | ALogp: | -1.7 |
HBD: | 6 | HBA: | 13 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 202.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 35 | QED Weighted: | 0.16 |
Caco-2 Permeability: | -6.003 | MDCK Permeability: | 0.00024478 |
Pgp-inhibitor: | 0.028 | Pgp-substrate: | 0.996 |
Human Intestinal Absorption (HIA): | 0.928 | 20% Bioavailability (F20%): | 0.012 |
30% Bioavailability (F30%): | 0.998 |
Blood-Brain-Barrier Penetration (BBB): | 0.159 | Plasma Protein Binding (PPB): | 33.87% |
Volume Distribution (VD): | 0.606 | Fu: | 26.20% |
CYP1A2-inhibitor: | 0.042 | CYP1A2-substrate: | 0.038 |
CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.4 |
CYP2C9-inhibitor: | 0.006 | CYP2C9-substrate: | 0.043 |
CYP2D6-inhibitor: | 0.007 | CYP2D6-substrate: | 0.047 |
CYP3A4-inhibitor: | 0.029 | CYP3A4-substrate: | 0.052 |
Clearance (CL): | 1.532 | Half-life (T1/2): | 0.853 |
hERG Blockers: | 0.107 | Human Hepatotoxicity (H-HT): | 0.691 |
Drug-inuced Liver Injury (DILI): | 0.678 | AMES Toxicity: | 0.26 |
Rat Oral Acute Toxicity: | 0.016 | Maximum Recommended Daily Dose: | 0.002 |
Skin Sensitization: | 0.314 | Carcinogencity: | 0.014 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.037 |
Respiratory Toxicity: | 0.023 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002949 | 0.842 | D07BSE | 0.374 | ||||
ENC003397 | 0.842 | D0T5BC | 0.360 | ||||
ENC0049112 | 0.383 | D0AD5C | 0.353 | ||||
ENC004460 | 0.353 | D0YV1Q | 0.351 | ||||
ENC003351 | 0.336 | D0D0SH | 0.350 | ||||
ENC002269 | 0.333 | D0Y3MO | 0.333 | ||||
ENC003820 | 0.331 | D07QQD | 0.332 | ||||
ENC003819 | 0.328 | D02HYK | 0.328 | ||||
ENC004854 | 0.324 | D0A8RX | 0.321 | ||||
ENC001939 | 0.310 | D04NDM | 0.321 |